phrykt

Gossamer Bio, Inc. (GOSS): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of GOSS were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Gossamer Bio

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns GOSS

169 funds and institutions reported GOSS shares worth $62.8M at the end of Q2 2026. The largest holder is D. E. Shaw & Co., Inc. with $6.7M.

10 largest owners, by value

D. E. Shaw & Co., Inc.$6.7M
683 Capital Management, LLC$6.5M
DeepCurrents Investment Group LLC$6M
Context Capital Management, LLC$4.8M
Worth Venture Partners, LLC$4.1M
Kalehua Capital Management LLC$3.7M
AQR Capital Management LLC$2.6M
Gsa Capital Partners LLP$2.5M
Wolverine Asset Management LLC$2.1M
Renaissance Technologies LLC$1.9M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
D. E. Shaw & Co., Inc.40.96M–$6.7M+10418%
683 Capital Management, LLC39.20M–$6.5M+684%
DeepCurrents Investment Group LLC37.67M–$6M–
Context Capital Management, LLC28.95M–$4.8M–
Worth Venture Partners, LLC25.02M–$4.1M–
Kalehua Capital Management LLC22.30M–$3.7M+26%
AQR Capital Management LLC15.63M–$2.6M+54%
Gsa Capital Partners LLP14.99M–$2.5M+361%
Wolverine Asset Management LLC12.89M–$2.1M–
Renaissance Technologies LLC11.63M–$1.9M+855%
Vanguard Capital Management LLC9.42M–$1.6M+0%
ARCH Venture Management, LLC8.06M–$1.3MNo change
Barclays PLC7.83M–$1.3M+155%
Octagon Capital Advisors LP7.75M–$1.3MNo change
BlackRock, Inc.7.67M–$1.3M-54%
Arrowstreet Capital, Limited Partnership7.57M–$1.2M–
Two Sigma Investments, LP7.43M–$1.2M+55%
Samsara Biocapital, LLC7.22M–$1.2MNo change
Qube Research & Technologies Ltd7.07M–$1.2M+44%
Corient Private Wealth LP5.63M–$927K+41%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No GOSS insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GOSS short interest

Low short interest. 0.3% of GOSS shares are sold short: about 1 share in 365. Over the last 12 reports the number of shares short went down 97%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.34M GOSS shares were sold short, 0.3% of the shares outstanding, down 6.8% from the report before. At the average daily volume of 178,080 shares, buying them all back would take about 7.5 trading days (days to cover).

Shares short, % of all shares

0.27%May 15Oct 3046.5%

Days to cover

7.5May 15Oct 3013.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.34M0.27%-7%178,0807.5
Oct 15, 20261.44M0.29%+16%280,4705.1
Sep 30, 20261.24M0.25%+30%353,4083.5
Sep 15, 2026948,6230.19%-99%186,9935.1
Aug 31, 202682.63M16.90%-5%29.61M2.8
Aug 14, 202686.79M17.75%-9%11.78M7.4
Jul 31, 202694.99M40.47%+30%63.58M1.5
Jul 15, 202673.18M31.18%+36%19.31M3.8
Jun 30, 202653.70M22.88%-4%16.67M3.2
Jun 15, 202656.21M23.95%-11%16.46M3.4
May 29, 202662.82M26.76%+54%22.10M2.8
May 15, 202640.84M17.40%+2%3.56M11.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Gossamer Bio company events

Gossamer Bio filed 22 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 28, 2026VoteReported shareholder vote results. Filing
  3. Sep 28, 2026AnnouncementGossamer Bio, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1), and… Filing
  4. Sep 23, 2026AnnouncementGossamer Bio, Inc. announced that it submitted a New Drug Application to the U.S. Food and Drug Administration in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension. Filing
  5. Sep 16, 2026LeadershipUpon the recommendation of the Nominating and Corporate Governance Committee, pursuant to the amended and restated bylaws of Gossamer Bio, Inc., the Board of Directors of the Company appointed Gregory A. Ciongoli to serve as a Class III director, effective September 16, 2026, with an initial term… Filing
  6. Sep 11, 2026AnnouncementThe Company issued a press release announcing the effectiveness of the Reverse Stock Split and Authorized Share Reduction. Filing
  7. Sep 9, 2026AnnouncementAs previously disclosed, on July 14, 2026, the stockholders of Gossamer Bio, Inc. approved thirty alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share, at one of thirty… Filing
  8. Sep 3, 2026RulesChanged its bylaws or articles. Filing
  9. Aug 26, 2026RulesChanged its bylaws or articles. Filing
  10. Aug 21, 2026AgreementGossamer Bio, Inc. entered into a securities purchase agreement with the purchasers named therein, including certain executive officers and directors of the Company, for the private placement of securities in two closings. Filing
  11. Aug 13, 2026ResultsReleased financial results. Filing
  12. Jul 27, 2026AgreementGossamer Bio, Inc., Gossamer Bio USA, Inc. (formerly GB002, Inc.) and Gossamer Bio 002 Ltd., on the one hand, and Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc. (together, “Chiesi”), on the other hand, entered into a Rights Reacquisition Agreement, under which Gossamer and Chiesi have agreed (a)… Filing
  13. Jul 15, 2026LeadershipThe Board of Directors of Gossamer Bio, Inc. previously approved, effective as of May 18, 2026, subject to stockholder approval and the occurrence of the closing date of the Company’s offer to exchange its outstanding $200.0 million in of 5.00% Convertible Senior Notes due 2027, an amendment and… Filing
  14. Jul 1, 2026AnnouncementShared information with investors. Filing
  15. Jun 17, 2026AnnouncementShared information with investors. Filing
  16. Jun 5, 2026AgreementNew Convertible Notes Indenture The New Convertible Notes delivered in exchange for the Early Tendered Notes were, and any New Convertible Notes delivered in exchange for remaining Existing Convertible Notes that are validly tendered in the Exchange Offer following the Extended Early Tender Date… Filing
  17. Jun 5, 2026VoteReported shareholder vote results. Filing
  18. Jun 2, 2026AnnouncementThe Company issued a press release announcing the extension of the early tender deadline of its previously announced exchange offer and consent solicitation to 5:00 p.m., New York City time, on June 2, 2026. Filing
  19. May 18, 2026LeadershipRestated Equity Plan In connection with the Transactions, the Board has approved an amendment and restatement of the Company’s 2019 Incentive Award Plan to increase the number of shares of Common Stock authorized for issuance thereunder, effective May 18, 2026, subject to the occurrence of the… Filing
  20. Apr 9, 2026ListingGossamer Bio, Inc. received a written notice from the staff of the Listing Qualifications Department of the Nasdaq Stock Market, notifying the Company that, for the 30 consecutive business day period between February 24, 2026 through April 7, 2026, the Company’s common stock, $0.0001 par value per… Filing
  21. Mar 17, 2026ResultsReleased financial results. Filing
  22. Feb 23, 2026AnnouncementGossamer Bio, Inc. announced topline results from its Phase 3 PROSERA study of seralutinib in patients with pulmonary arterial hypertension (PAH). Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Gossamer Bio financials

Famous investors that hold GOSS

1 of the 50 well-known investors we track reported holding GOSS in their latest 13F filing. The largest position is Jim Simons's, worth $329K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202627,725$329K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named GOSS in the last 120 days.

FiledHolderFormStake
Nov 16, 2026DeepCurrents Investment Group LLC13G/A3.8%
Nov 16, 2026DeepCurrents Investment Group LLC13G/A3.8%
Nov 6, 2026FMR LLC13G10.9%
Nov 6, 2026FMR LLC13G10.9%
Nov 6, 2026Opaleye Management Inc.13G/A7.0%
Nov 6, 2026Opaleye Management Inc.13G/A7.0%
Oct 29, 2026D. E. Shaw Valence Portfolios, L.L.C.13D/A4.0%
Oct 29, 2026D. E. Shaw Valence Portfolios, L.L.C.13D/A4.0%
Oct 8, 2026D. E. Shaw Valence Portfolios, L.L.C.13D/A5.9%
Oct 8, 2026D. E. Shaw Valence Portfolios, L.L.C.13D/A5.9%

Questions about Gossamer Bio, Inc. (GOSS) stock

Who owns the most GOSS stock?

The largest reported owner of Gossamer Bio, Inc. (GOSS) is D. E. Shaw & Co., Inc.. In total, 169 funds and institutions reported holding GOSS at the end of Q2 2026. See the largest owners.

Are GOSS insiders buying or selling?

No GOSS insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in GOSS?

As of Oct 30, 2026, 1.34M GOSS shares were sold short, 0.3% of the shares outstanding, down 6.8% from the report before. At the average daily volume of 178,080 shares, buying them all back would take about 7.5 trading days (days to cover). See the history.

Which famous investors hold GOSS?

1 of the 50 well-known investors we track reported GOSS in their latest 13F filing, including Jim Simons. The largest position is worth $329K. See all holders.

Executive pay

Gossamer Bio's chief executive was paid a total of $2.3M for the year ended Dec 31, 2025, up 15% from $2M the year before. In the last 12 months, Gossamer Bio's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$2.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$9.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.